Jardine Matheson is making a powerful move by acquiring Australia's I-MED for an impressive $2.4 billion enterprise value, dramatically boosting its healthcare portfolio. This bold step marks a strategic leap into the fast-growing world of medical diagnostics, positioning the company at the forefront of industry innovation
AstraZeneca is making a bold leap with a $15 billion investment in China through 2030, cementing its role as a leader in next-generation innovative medicine and expanding its presence in one of the world's fastest-growing healthcare markets
Australia's Medical Research Future Fund boldly defies the Trump administration's anti-science stance, investing billions into revolutionary innovations and securing Australia's spot as a global powerhouse in medical research
